Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NAWID M SARWARI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1649698630
CMS profile
4226112
Location
ANAHEIM, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$5,386.30

248 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $5,101.37 245
Education $284.93 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $394.11 17
E.R. Squibb & Sons, L.L.C. $318.77 22
AstraZeneca Pharmaceuticals LP $289.53 14
Celgene Corporation $285.67 12
Astellas Pharma US Inc $257.69 5
Bayer Healthcare Pharmaceuticals Inc. $256.29 8
PFIZER INC. $254.11 16
Takeda Pharmaceuticals U.S.A., Inc. $214.72 9
GlaxoSmithKline, LLC. $211.91 15
Merck Sharp & Dohme LLC $197.54 9
Incyte Corporation $182.04 9
Exelixis Inc. $172.66 6
Eisai Inc. $149.02 7
Janssen Biotech, Inc. $141.53 7
Gilead Sciences, Inc. $107.84 5
Puma Biotechnology, Inc. $104.65 4
Karyopharm Therapeutics Inc. $99.29 4
Pharmacyclics LLC, An AbbVie Company $99.09 4
BeiGene USA, Inc. $94.57 4
ARRAY BIOPHARMA INC $83.94 6
Daiichi Sankyo Inc. $77.66 3
Alexion Pharmaceuticals, Inc. $66.20 3
Seagen Inc. $66.13 3
TAIHO ONCOLOGY, INC. $65.34 3
Sumitomo Pharma America, Inc. $63.74 2
Mirati Therapeutics, Inc. $61.73 3
Kite Pharma, Inc. $61.53 2
Boehringer Ingelheim Pharmaceuticals, Inc. $61.24 3
Rigel Pharmaceuticals, Inc. $57.79 3
Emmaus Medical, Inc. $53.91 3
Blueprint Medicines Corporation $53.68 2
ImmunoGen, Inc. $52.75 2
GENZYME CORPORATION $50.51 2
Stemline Therapeutics Inc. $50.41 2
Genentech USA, Inc. $48.17 2
SOBI, INC $45.15 2
Ipsen Biopharmaceuticals, Inc $44.48 2
Agios Pharmaceuticals, Inc. $37.73 2
Amgen Inc. $37.48 2
Adaptive Biotechnologies Corporation $37.31 1
AVEO Pharmaceuticals, Inc. $36.93 2
EMD Serono, Inc. $34.65 1
Cumberland Pharmaceuticals, Inc. $33.66 1
Novocure Inc. $32.79 2
Organon LLC $32.36 2
CSL Behring $29.73 1
Alnylam Pharmaceuticals Inc. $27.53 1
Dendreon Pharmaceuticals LLC $23.20 1
Regeneron Healthcare Solutions, Inc. $22.25 1
Foundation Medicine, Inc. $20.96 1
SERVIER PHARMACEUTICALS LLC $20.24 1
Deciphera Pharmaceuticals Inc. $19.31 1
MorphoSys, US Inc. $15.11 1
ACCORD HEALTHCARE, INC. $14.96 1
Acrotech Biopharma Inc. $14.71 1

Page 4 of 5; records 151–200 of 248 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NAWID M SARWARI

NPI 1649698630 · CMS profile ID 4226112

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ANAHEIM, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 248 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649698630?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NAWID M SARWARI, NPI 1649698630, CMS profile ID 4226112. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 248 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649698630?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). NAWID M SARWARI, NPI 1649698630, CMS profile ID 4226112. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 248 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649698630?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
NAWID M SARWARI, NPI 1649698630, CMS profile ID 4226112, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 248 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1649698630?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

248 matching records · $5,386.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 248 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 248.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Karyopharm Therapeutics Inc. $29.5905/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056906157 CMS
Merck Sharp & Dohme LLC $22.8605/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048872617 CMS
Janssen Biotech, Inc. $25.9005/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988175749 CMS
GlaxoSmithKline, LLC. $25.2405/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001301055 CMS
AstraZeneca Pharmaceuticals LP $19.0405/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015848385 CMS
Gilead Sciences, Inc. $23.6405/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025685893 CMS
Agios Pharmaceuticals, Inc. $15.8605/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056213315 CMS
PFIZER INC. $21.2405/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050362693 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.1805/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000504311 CMS
Seagen Inc. $24.5505/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995836019 CMS
Celgene Corporation $7.9405/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015568913 CMS
Exelixis Inc. $33.1605/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044552293 CMS
ARRAY BIOPHARMA INC $19.6605/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049298029 CMS
Novartis Pharmaceuticals Corporation $24.9205/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993286345 CMS
Mirati Therapeutics, Inc. $18.1705/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058002593 CMS
Janssen Biotech, Inc. $22.0705/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988175779 CMS
Novartis Pharmaceuticals Corporation $10.0305/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993286319 CMS
Eisai Inc. $19.0104/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023325179 CMS
Stemline Therapeutics Inc. $15.9004/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040034361 CMS
Gilead Sciences, Inc. $16.6204/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025942635 CMS
Amgen Inc. $21.6604/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020647909 CMS
GlaxoSmithKline, LLC. $17.0204/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001301019 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.4804/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055584737 CMS
SOBI, INC $24.0104/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038076475 CMS
Dendreon Pharmaceuticals LLC $23.2004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060290447 CMS
E.R. Squibb & Sons, L.L.C. $21.8204/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015568881 CMS
Novartis Pharmaceuticals Corporation $14.2004/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993286347 CMS
Celgene Corporation $31.4504/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015568897 CMS
PFIZER INC. $15.9504/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050555209 CMS
Novartis Pharmaceuticals Corporation $33.0104/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993286341 CMS
GlaxoSmithKline, LLC. $19.1104/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001301043 CMS
Seagen Inc. $25.1804/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995835961 CMS
Pharmacyclics LLC, An AbbVie Company $23.5404/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998294743 CMS
BeiGene USA, Inc. $22.4604/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051184237 CMS
TAIHO ONCOLOGY, INC. $24.4804/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055224819 CMS
Janssen Biotech, Inc. $26.6904/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988175787 CMS
CSL Behring $29.7304/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042996432 CMS
Organon LLC $16.8204/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046825945 CMS
Alexion Pharmaceuticals, Inc. $21.6503/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017036903 CMS
E.R. Squibb & Sons, L.L.C. $17.3103/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015568697 CMS
GlaxoSmithKline, LLC. $14.4403/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001300961 CMS
MorphoSys, US Inc. $15.1103/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060327537 CMS
ARRAY BIOPHARMA INC $15.1203/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050572367 CMS
Merck Sharp & Dohme LLC $20.0803/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048440341 CMS
PFIZER INC. $21.6503/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050586457 CMS
Adaptive Biotechnologies Corporation $37.3103/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022973115 CMS
Bayer Healthcare Pharmaceuticals Inc. $26.1703/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000523399 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.5903/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997041361 CMS
Regeneron Healthcare Solutions, Inc. $22.2503/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999414221 CMS
Novartis Pharmaceuticals Corporation $30.3803/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993286337 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $245.89 2
PY2020 $3,704.99 64
PY2021 $7,521.17 161
PY2022 $4,395.48 214
PY2023 $5,386.30 248
PY2024 $6,680.72 252
PY2025 $6,044.07 247

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $32,254.58 38
PY2024 Principal investigator $21,904.46 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Hoffmann-La Roche Limited $40.89 12/19/2025 Non-covered Recipient Entity
HELIOS CR INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211612688
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731074
Principal investigator 1 Hoffmann-La Roche Limited $6,812.10 12/01/2025 Non-covered Recipient Entity
HELIOS CR INC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211612692
Principal investigator 1 Hoffmann-La Roche Limited $300.00 11/05/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612684
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731072
Principal investigator 1 Hoffmann-La Roche Limited $35.90 10/24/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612664
Principal investigator 1 Hoffmann-La Roche Limited $39.92 10/24/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612672
Principal investigator 1 Hoffmann-La Roche Limited $36.58 10/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612652
Principal investigator 1 Hoffmann-La Roche Limited $39.50 10/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612676
Principal investigator 1 Hoffmann-La Roche Limited $472.50 10/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612680
Principal investigator 1 Hoffmann-La Roche Limited $212.50 10/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612644
Principal investigator 1 Hoffmann-La Roche Limited $7,352.10 10/08/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612660
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731070
Principal investigator 1 Hoffmann-La Roche Limited $2,112.75 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612640
Principal investigator 1 Hoffmann-La Roche Limited $11,194.20 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612648
Principal investigator 1 Hoffmann-La Roche Limited $250.00 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612655
Principal investigator 1 Hoffmann-La Roche Limited $108.00 10/01/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612669
Principal investigator 1 Hoffmann-La Roche Limited $250.00 09/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612602
Principal investigator 1 Hoffmann-La Roche Limited $445.50 09/17/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612635
Principal investigator 1 Hoffmann-La Roche Limited $45.34 09/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612617
Principal investigator 1 Hoffmann-La Roche Limited $37.34 09/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612625
Principal investigator 1 Hoffmann-La Roche Limited $30.85 09/10/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612631
Principal investigator 1 Hoffmann-La Roche Limited $250.00 09/03/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612606
Principal investigator 1 Hoffmann-La Roche Limited $41.88 09/03/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612628
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731050
Principal investigator 1 Hoffmann-La Roche Limited $12.94 08/22/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612621
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731048
Principal investigator 1 Boehringer Ingelheim International GmbH $509.10 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731054
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731056
Principal investigator 1 Boehringer Ingelheim International GmbH $539.46 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731058
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731060
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731062
Principal investigator 1 Boehringer Ingelheim International GmbH $5.68 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731064
Principal investigator 1 Boehringer Ingelheim International GmbH $143.00 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731066
Principal investigator 1 Boehringer Ingelheim International GmbH $30.66 07/28/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731068
Principal investigator 1 Hoffmann-La Roche Limited $29.82 07/25/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612609
Principal investigator 1 Hoffmann-La Roche Limited $25.87 07/25/2025 Non-covered Recipient Entity
HELIOS CR INC
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors No dispute reported 06/30/2026 1211612613
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
The Oncology Institute
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220731052